Details
Stereochemistry | RACEMIC |
Molecular Formula | C7H17N2O2.Cl |
Molecular Weight | 196.675 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CC(C[N+](C)(C)C)OC(N)=O
InChI
InChIKey=XXRMYXBSBOVVBH-UHFFFAOYSA-N
InChI=1S/C7H16N2O2.ClH/c1-6(11-7(8)10)5-9(2,3)4;/h6H,5H2,1-4H3,(H-,8,10);1H
Bethanechol is a parasympathomimetic choline carbamate that selectively stimulates muscarinic receptors with little effect on nicotinic receptors. Bethanechol is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 |
4.01 null [pKi] | ||
Target ID: CHEMBL211 |
4.04 null [pKi] | ||
Target ID: CHEMBL245 |
4.15 null [pKi] | ||
Target ID: CHEMBL1821 |
4.03 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Bethanechol chloride Approved UseBethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. Launch Date1948 |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg single, intramuscular MTD Dose: 50 mg Route: intramuscular Route: single Dose: 50 mg Sources: |
unhealthy, 31-71 n = 9 Health Status: unhealthy Condition: duodenal ulcer (patients after proximal gastric vagotomy) Age Group: 31-71 Sex: M+F Population Size: 9 Sources: |
|
50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
Other AEs: Abdominal discomfort, Salivation... Other AEs: Abdominal discomfort Sources: Salivation Flushed skin Sweating Nausea Vomiting |
20 mg 3 times / day multiple, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: bladder dysfunction after type III radical hysterectomy Sex: F Population Size: 31 Sources: |
Other AEs: Nausea, Abdominal distension... Other AEs: Nausea (12.9%) Sources: Abdominal distension (6.4%) Abdominal cramps (9.7%) |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Other AEs: Sweating, Flushing... Other AEs: Sweating (27%) Sources: Flushing (27%) Stomach cramps (12%) Diarrhea (12%) Headache (17%) Dizziness (17%) Visual disorders NEC (12%) Urination abnormal NOS (28%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal discomfort | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Flushed skin | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Nausea | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Salivation | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Sweating | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Vomiting | 50 mg 4 times / day multiple, oral Overdose Dose: 50 mg, 4 times / day Route: oral Route: multiple Dose: 50 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: urinary retention Sources: |
|
Nausea | 12.9% | 20 mg 3 times / day multiple, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: bladder dysfunction after type III radical hysterectomy Sex: F Population Size: 31 Sources: |
Abdominal distension | 6.4% | 20 mg 3 times / day multiple, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: bladder dysfunction after type III radical hysterectomy Sex: F Population Size: 31 Sources: |
Abdominal cramps | 9.7% | 20 mg 3 times / day multiple, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy n = 31 Health Status: unhealthy Condition: bladder dysfunction after type III radical hysterectomy Sex: F Population Size: 31 Sources: |
Diarrhea | 12% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Stomach cramps | 12% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Visual disorders NEC | 12% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Dizziness | 17% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Headache | 17% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Flushing | 27% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Sweating | 27% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
Urination abnormal NOS | 28% | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: xerostomia Sex: M+F Population Size: 18 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Aging effects on contractility of longitudinal and circular detrusor and trigone of rat bladder. | 2001 Aug |
|
PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats. | 2001 Aug |
|
Regional differences in the response of feline esophageal smooth muscle to stretch and cholinergic stimulation. | 2001 Dec |
|
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. | 2001 Jul |
|
Differences in Ca(2+) signaling underlie age-specific effects of secretagogues on colonic Cl(-) transport. | 2001 Mar |
|
Inhibition of gastric acid secretion by saiboku-to, an oriental herbal medicine, in rats. | 2001 May |
|
Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. | 2001 Nov |
|
Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. | 2001 Sep |
|
Secretion of the trefoil factor TFF3 from the isolated vascularly perfused rat colon. | 2001 Sep 15 |
|
Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways. | 2002 Aug |
|
Different role of the histamine H3-receptor in vagal-, betanechol-, pentagastrin-induced gastric acid secretion in anaesthetized rats. | 2002 Jul |
|
Generation of a cell line with smooth muscle phenotype from hypertrophied urinary bladder. | 2002 Jul |
|
Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. | 2002 Jun |
|
Pharmacologic treatment of anal fissure with botoxin, diltiazem, or bethanechol. | 2002 May-Jun |
|
Antagonistic effects of CompB on orphanin FQ-induced colonic contractions in rats. | 2002 Nov 1 |
|
Antisecretory effect of somatostatin on gastric acid via inhibition of histamine release in isolated mouse stomach. | 2002 Oct 4 |
|
[Cluttering/tachyphemia]. | 2003 |
|
Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride. | 2003 Apr |
|
Role of leptin in the control of postprandial pancreatic enzyme secretion. | 2003 Dec |
|
Muscarinic receptors couple to modulation of nicotinic ACh receptor desensitization in myenteric neurons. | 2003 Jul |
|
Selective activation by photodynamic action of cholecystokinin receptor in the freshly isolated rat pancreatic acini. | 2003 Jun |
|
ERG K+ channels modulate the electrical and contractile activities of gallbladder smooth muscle. | 2003 Mar |
|
An embryonic chick pancreas organ culture model: characterization and neural control of exocrine release. | 2003 May 30 |
|
P2X2 subunits contribute to fast synaptic excitation in myenteric neurons of the mouse small intestine. | 2003 Nov 1 |
|
Pharmacological characterization of isolated human prostate. | 2003 Sep |
|
Acetylcholine release in the pontine reticular formation of C57BL/6J mouse is modulated by non-M1 muscarinic receptors. | 2004 |
|
Successful pharmacotherapy for an adult case with prolonged symptoms of postganglionic cholinergic dysautonomia. | 2004 |
|
Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. | 2004 Jul |
|
Acute exposure to methylmercury causes Ca2+ dysregulation and neuronal death in rat cerebellar granule cells through an M3 muscarinic receptor-linked pathway. | 2004 Jul |
|
Fetal gastrointestinal motility in a rabbit model of gastroschisis. | 2004 Mar |
|
Lower urinary tract dysfunction in Machado-Joseph disease: a study of 11 clinical-urodynamic observations. | 2004 Mar 15 |
|
Expressions of CCAAT-enhancer-binding proteins and c-Myc in the parotid gland of the rat: in vivo effects of isoprenaline, bethanechol, vasoactive intestinal peptide and food intake. | 2004 May |
Patents
Sample Use Guides
The usual adult oral dose ranges from 10 to 50 mg three or four times a day. The minimum effective dose is determined by giving 5 to 10 mg initially and repeating the same amount at hourly intervals until satisfactory response occurs, or until a maximum of 50 mg has been given. The effects of the drug sometimes appear within 30 minutes and are usually maximal within 60 to 90 minutes. The drug effects persist for about one hour.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
590-63-6
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
30783
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
DBSALT000234
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
11548
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
H4QBZ2LO84
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
DTXSID2022676
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
1071009
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL1482
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
m2457
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
47088
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
209-686-8
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
C28866
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
H4QBZ2LO84
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
100000076855
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY | |||
|
SUB13064MIG
Created by
admin on Fri Dec 15 16:20:59 GMT 2023 , Edited by admin on Fri Dec 15 16:20:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD